Amit Bilgi

3 Reasons To Buy Parexel

Parexel (NASDAQ:PRXL) is one of those companies that fall into the category of being large and fairly profitable, but not exactly in the public's eye. The one possible incident that may possibly ring a bell is a 2006 trial by the now-defunct German pharmaceutical company TeGenero, which Parexel ran. As a brief summary, TeGenero's now infamous drug TGN1412 was tested on humans for the first time and led to multiple organ failure in six patients, launching a firestorm in the process, as one would imagine. Granted, this is far into Parexel's past and has little bearing on the massive potential the company has in the coming months.

Parexel belongs to the family of contract research organizations (...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details